Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M S Rafii

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
The Journal of Prevention of Alzheimer'S Disease|March 24, 2017
Active Immunotherapy for Alzheimer's Disease: The Road AheadM S Rafii
The Journal of Prevention of Alzheimer'S Disease|June 25, 2023
Editorial: Appropriate Use Recommendations for LecanemabM S Rafii
The Journal of Prevention of Alzheimer'S Disease|December 18, 2020
Integrating Biomarker Outcomes into Clinical Trials for Alzheimer's Disease in Down SyndromeM S Rafii, S Zaman, B L Handen
Pediatric and Developmental Pathology : the Official Journal of the Society for Pediatric Pathology and the Paediatric Pathology Society|April 7, 1999
Approximate doubling of numbers of neurons in postnatal human cerebral cortex and in 35 specific cytoarchitectural areas from birth to 72 monthsW R Shankle, M S Rafii, B H Landing, et al.
AJNR. American Journal of Neuroradiology|June 15, 2013
An expanded role for neuroimaging in the evaluation of memory impairmentR S Desikan, M S Rafii, J B Brewer, et al.
Journal of Theoretical Biology|June 19, 1998
Evidence for a postnatal doubling of neuron number in the developing human cerebral cortex between 15 months and 6 yearsW R Shankle, B H Landing, M S Rafii, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 26, 1999
Agrin in Alzheimer's disease: altered solubility and abnormal distribution within microvasculature and brain parenchymaJ E Donahue, T M Berzin, M S Rafii, et al.
Neurology|April 20, 2011
A phase II trial of huperzine A in mild to moderate Alzheimer diseaseM S Rafii, S Walsh, J T Little, et al.
The Journal of Prevention of Alzheimer'S Disease|July 9, 2025
CTAD taskforce: genetic therapies in Alzheimer's diseaseD Jakabek, A M Isaacs, B De Strooper, et al.
The Journal of Prevention of Alzheimer'S Disease|July 24, 2024
Safety Profile of a Cognitively Unimpaired Older Population with Elevated Cerebral Amyloid in a 4.5-Year Clinical TrialR Yaari, K C Holdridge, M Mancini, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
The Journal of Prevention of Alzheimer'S Disease|March 24, 2017
Active Immunotherapy for Alzheimer's Disease: The Road AheadM S Rafii
The Journal of Prevention of Alzheimer'S Disease|June 25, 2023
Editorial: Appropriate Use Recommendations for LecanemabM S Rafii
The Journal of Prevention of Alzheimer'S Disease|December 18, 2020
Integrating Biomarker Outcomes into Clinical Trials for Alzheimer's Disease in Down SyndromeM S Rafii, S Zaman, B L Handen
Pediatric and Developmental Pathology : the Official Journal of the Society for Pediatric Pathology and the Paediatric Pathology Society|April 7, 1999
Approximate doubling of numbers of neurons in postnatal human cerebral cortex and in 35 specific cytoarchitectural areas from birth to 72 monthsW R Shankle, M S Rafii, B H Landing, et al.
AJNR. American Journal of Neuroradiology|June 15, 2013
An expanded role for neuroimaging in the evaluation of memory impairmentR S Desikan, M S Rafii, J B Brewer, et al.
Journal of Theoretical Biology|June 19, 1998
Evidence for a postnatal doubling of neuron number in the developing human cerebral cortex between 15 months and 6 yearsW R Shankle, B H Landing, M S Rafii, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 26, 1999
Agrin in Alzheimer's disease: altered solubility and abnormal distribution within microvasculature and brain parenchymaJ E Donahue, T M Berzin, M S Rafii, et al.
Neurology|April 20, 2011
A phase II trial of huperzine A in mild to moderate Alzheimer diseaseM S Rafii, S Walsh, J T Little, et al.
The Journal of Prevention of Alzheimer'S Disease|July 9, 2025
CTAD taskforce: genetic therapies in Alzheimer's diseaseD Jakabek, A M Isaacs, B De Strooper, et al.
The Journal of Prevention of Alzheimer'S Disease|July 24, 2024
Safety Profile of a Cognitively Unimpaired Older Population with Elevated Cerebral Amyloid in a 4.5-Year Clinical TrialR Yaari, K C Holdridge, M Mancini, et al.
Pageof 2